Volume 19 Supplement 2

Eighth International Symposium on Intensive Care and Emergency Medicine for Latin America

Open Access

Heart rate variability in HIV-infected and AIDS

  • Gabriela AM Galdino1,
  • Fernanda R Moraes1,
  • Gesileny V Silva1 and
  • Marilita F Accioly1
Critical Care201519(Suppl 2):P6

https://doi.org/10.1186/cc14662

Published: 28 September 2015

Introduction

The availability of antiretroviral therapy (ART) has resulted in a dramatic reduction in HIV-associated mortality [1]. However, it is also known to induce an array of adverse effects [24], as autonomic dysfunction. The use of heart rate variability (HRV), allows the assessment of relative contribution of sympathetic and parasympathetic involvement [1].

Objective

The objective of this study was to assess the presence of autonomic dysfunction in HIV-infected and acquired immunodeficiency syndrome (AIDS) patients that receive ART. In order to do so, analysis of HRV was applied.

Methods

A total of 15 subjects with HIV and 34 with AIDS were analyzed. To capture HRV, the heart rate monitor Polar RS810CX was used. The HRV was recorded in a supine position for 20 minutes, and then while performing the respiratory sinus arrhythmia (RSA). The statistical analysis was calculated using ANOVA and Pearson correlation (α = 5%).

Results

The HIV group had average duration of exposure to the virus of 4.5 ± 3.5 years, and the AIDS group 12.6 ± 6.6 years, both under ART. Only the %REC presented suggestive statistically significant difference (Table 1) of greater parasympathetic modulation in the AIDS group, while the RSA did not show a statistically significant difference (p >0.05).
Table 1

Time domain analysis.

HRV parameter (ms/%)

HIV

AIDS

pvalue

RMSSD

18.5 (11.5)

23.7 (17)

<0.314

PNN50

3.9 (6.8)

6.9 (9.9)

<0.340

%REC

38.3 (11.2)

32.7 (6.7)

<0.002

Data presented as mean (SD)

Conclusion

Based on chaos theory, %REC was more sensitive to identify lower parasympathetic modulation in the HIV group, probably due to shorter exposure to antiretroviral therapy. Therefore, it is suggested that the medication used by the population modifies the HRV.

Declarations

Acknowledgements

Supported by FAPEMIG.

Authors’ Affiliations

(1)
Universidade Federal do Triângulo Mineiro

References

  1. Lebech AM, Kristoffersen US, Mehlsen J, Wiinberg N, Petersen CL, Hesse B, et al: Autonomic dysfunction in HIV patients on antiretroviral therapy: studies of heart rate variability. Clin Physiol Funct Imaging. 2007, 27 (6): 363-367. 10.1111/j.1475-097X.2007.00760.x.View ArticlePubMedGoogle Scholar
  2. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998, 12 (7): F51-F58. 10.1097/00002030-199807000-00003.View ArticlePubMedGoogle Scholar
  3. Dube MP, Sattler FR: Metabolic complications of antiretroviral therapies. AIDS Clin Care. 1998, 10 (6): 41-44.PubMedGoogle Scholar
  4. Ramirez-Villegas JF, Lam-Espinosa E, Ramirez-Moreno DF, Calvo-Echeverry PC, AgredoRodriguez W: Heart rate variability dynamics for the prognosis of. cardiovascular risk. PLoS One. 2011, 6 (2): e17060-10.1371/journal.pone.0017060.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Galdino et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement